论文部分内容阅读
斯堪的纳维亚辛伐他汀生存研究(4S)首次证实降脂治疗能提高生存率,该研究中多数患者达到了治疗标准,即总胆固醇(TC)<5.2mmol/L;而第三次国家健康和营养检查报道提示只有60％患者能达到国家胆固醇教育计划(NCEP)的治疗标准,说明一些病人还需要进一步的降脂治疗。这一多中心随机双盲平行对照研究就是评价辛伐他汀80mg/d降脂治疗的效果和安全性。
The Scandinavian Simvastatin Survival Study (4S) demonstrated for the first time that lipid-lowering therapy increased survival, with most patients in the study achieving the treatment criteria of <5.2 mmol / L total cholesterol (TC); and the third National Health and Nutrition Examination reports suggest that only 60% of patients meet the National Cholesterol Education Program (NCEP) treatment criteria, indicating that some patients also need further lipid-lowering treatment. This multicenter randomized, double-blind, parallel-controlled study was to evaluate the efficacy and safety of simvastatin 80 mg / d lipid-lowering therapy.